CSI Market
Sign In | Register

La Jolla Pharmaceutical (LJPC) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access LJPC quarterly Cash Flow →
The quarterly cash flow data below helps track how La Jolla Pharmaceutical's liquidity profile has evolved over recent quarters.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2021)
12 Months 		(Dec 31 2020) (Dec 31 2019) (Dec 31 2018) (Dec 31 2017)
Operating Activities
Income19.66
Depreciation & amortization0.11
Amortization of Other Assets1.55
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.27
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation4.48
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total0.00
Warrant Grantsto Third Parties Compensation Expense-
Issuance Of Temporary Equity For Services-
Non Cash Interest Expense7.14
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value-
Change In Fair Value Of Contingent Value Rights-
Amortization Of Right Of Use Lease Assets0.22
Gain On Changes In Fair Value Of Contingent Value Rights-0.73
Increase Decrease In Contract With Customer Liability2.66
Gain Loss On Sale Of Short Term Investments-0.22
Gain On Forgiveness Of Paycheck Protection Program Loan-
Gain On Sale Of Non Controlling Equity Interest-
Increase Decrease Operating Lease Liability-
Income taxes0.00
Unrealized Gain (Loss) on Derivatives0.00
Increase (Decrease) in Accounts Receivable-2.78
Increase (Decrease) in Accounts Payable and Accrued Liabilities-0.48
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-0.73
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.37
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities28.24
Investing Activities
Capital Expenditures-0.01
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.01
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-3.22
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-21.26
Reclassification Of Preferred Stock Not Currently Redeemable-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents21.26
Proceeds From Royalties Financing-
Proceeds From Issuance Of Common Stock From Employee Share Purchase Program0.44
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-2.79
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow28.24
Total Cash Flow25.45
4 historic quarters locked

Sign in to unlock the full La Jolla Pharmaceutical cash flow history.

Sign In Create Free Account

About La Jolla Pharmaceutical Co Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001564590-22-029398

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License